WIN54954
WIN54954 is a broad-spectrum antipicornavirus drug.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | WIN54954 |
|---|---|
| Iupac 化学名称 | Isoxazole, 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methyl- |
| 同义词 | WIN54954; WIN-54954; WIN 54954; |
| 英文同义词 | WIN54954; WIN-54954; WIN 54954; |
| 分子式 | C18H20Cl2N2O3 |
| 分子量 | 383.27 |
| Smile | CC1=NOC(CCCCCOC2=C(Cl)C=C(C3=NCCO3)C=C2Cl)=C1 |
| InChiKey | JJDHAOLOHQTGMG-UHFFFAOYSA-N |
| InChi | InChI=1S/C18H20Cl2N2O3/c1-12-9-14(25-22-12)5-3-2-4-7-23-17-15(19)10-13(11-16(17)20)18-21-6-8-24-18/h9-11H,2-8H2,1H3 |
| Cas号 | 107355-45-3 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: See DM, Tilles JG. WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus. Antimicrob Agents Chemother. 1993 Aug;37(8):1593-8. doi: 10.1128/AAC.37.8.1593. PMID: 8215268; PMCID: PMC188025.
2: Heim A, Pfetzing U, Müller G, Grumbach IM. Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts. Antiviral Res. 1998 Jan;37(1):47-56. doi: 10.1016/s0166-3542(97)00056-9. PMID: 9497072.
3: Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ, McKinlay MA. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74. doi: 10.1128/AAC.33.12.2069. PMID: 2559655; PMCID: PMC172823.
4: Ilbäck NG, Wesslén L, Pauksen K, Stålhandske T, Friman G, Fohlman J. Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease. Scand J Infect Dis Suppl. 1993;88:117-23. PMID: 8390714.
5: See DM, Tilles JG. Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954. Antimicrob Agents Chemother. 1992 Feb;36(2):425-8. doi: 10.1128/AAC.36.2.425. PMID: 1318683; PMCID: PMC188451.
6: Turner RB, Dutko FJ, Goldstein NH, Lockwood G, Hayden FG. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother. 1993 Feb;37(2):297-300. doi: 10.1128/AAC.37.2.297. PMID: 8383943; PMCID: PMC187656.
7: Kytö V, Saraste A, Fohlman J, Ilbäck NG, Harvala H, Vuorinen T, Hyypiä T. Cardiomyocyte apoptosis after antiviral WIN 54954 treatment in murine coxsackievirus B3 myocarditis. Scand Cardiovasc J. 2002 May;36(3):187-92. doi: 10.1080/cdv.36.3.187.192. PMID: 12079640.
8: Pauksen K, Ilbäck NG, Friman G, Fohlman J. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations. Scand J Infect Dis Suppl. 1993;88:125-30. PMID: 8390715.
9: Egan JA, Nugent RP, Filer CN. Potent antiviral agent WIN 54954: high specific activity labelling with tritium. Appl Radiat Isot. 2004 Jun;60(6):851-3. doi: 10.1016/j.apradiso.2004.03.002. PMID: 15110350; PMCID: PMC7127203.
10: Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self- emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992 Jan;9(1):87-93. doi: 10.1023/a:1018987928936. PMID: 1589415.
